Loxo beefs up its ge­net­ics-based can­cer drug pipeline with an un­usu­al $40M deal

Af­ter build­ing on its rep as a ge­net­i­cal­ly-fo­cused can­cer drug com­pa­ny at AS­CO with the lat­est up­date on larotrec­tinib (LOXO-101), Loxo On­col­o­gy is now beef­ing up its pipeline in search of an­oth­er drug that can be used for a care­ful­ly de­fined pa­tient group.

The Stam­ford, CT-based biotech has carved out a Bru­ton’s ty­ro­sine ki­nase (BTK) in­hibitor pro­gram from Redx Phar­ma for $40 mil­lion. Un­usu­al­ly, it’s a straight cash deal for Loxo and Redx — no mile­stones or roy­al­ties ap­ply here. That is rare to see for a pre­clin­i­cal drug that isn’t ex­pect­ed to be­gin hu­man test­ing un­til next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER